{"id":"W4402565436","doi":"10.1016/j.annonc.2024.08.2272","title":"LBA33 ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Stand Up To Cancer; PharmaMar; Vifor Pharma; Eisai; Cancer Australia; European Commission; Canadian Cancer Society; Seagen; Aldeyra Therapeutics; MacroGenics; Veracyte; Austrian Science Fund; Amgen; Deciphera Pharmaceuticals; Clovis Oncology; Les Laboratories Pierre Fabre; National Health and Medical Research Council; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Mersana Therapeutics; Stryker; Pfizer; Incyte; EQRx; F. Hoffmann-La Roche; Verastem Oncology; Array BioPharma; Hexal AG; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Exelixis; Sanofi; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Medicine; Ovarian cancer; Oncology; Internal medicine; Randomized controlled trial; Maintenance therapy; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002362571,0.002115972,0.003687728,0.0004850212,0.0004962897,0.001301655,0.001481892,0.001805703,0.006213123],"category_scores_gemma":[0.001317764,0.0008631965,0.002193325,0.0007751114,0.001768509,0.001262085,0.0006211275,0.005754738,0.001350535],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001554585,"about_ca_system_score_gemma":0.002157152,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002190464,"about_ca_topic_score_gemma":0.005340611,"domain_scores_codex":[0.9991793,0.0004326471,0.00003357265,0.0001407827,0.00005036863,0.0001632984],"domain_scores_gemma":[0.9986789,0.0002608572,0.0002770879,0.0001449376,0.00004819136,0.000590094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9673154,0.01192945,0.001270876,0.0001989301,0.000716782,0.0000288994,0.00004062453,0.0004014449,0.003026713,0.0000937724,0.0009117611,0.0140653],"study_design_scores_gemma":[0.8978131,0.09715813,0.003279298,0.00001541653,0.0003506312,0.00003315733,0.0000175263,0.0004187596,0.0002938651,0.00007822995,0.0005268151,0.00001505478],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901491,0.002080744,0.0005131958,0.0008134822,0.0002888543,0.002420651,0.001729351,0.0001350923,0.001869381],"genre_scores_gemma":[0.9834706,0.001740895,0.002030078,0.001525465,0.0004022849,0.003923788,0.003735206,0.0000523557,0.003119223],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006213123,"threshold_uncertainty_score":0.02078497,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04611177208356617,"score_gpt":0.4064169927609281,"score_spread":0.360305220677362,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}